Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2014; 20(17): 5098-5103
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5098
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5098
Table 1 Relationship between pre-radiotherapy serum vascular endothelial growth factor level and clinical characteristics of esophageal cancer patients
Variable | Cases | VEGF (ng/L) | t (F) | P value |
Sex | 1.11 | > 0.05 | ||
Male | 62 | 120.78 ± 44.72 | ||
Female | 24 | 135.92 ± 61.00 | ||
Age, yr | 0.89 | > 0.05 | ||
< 55 | 71 | 126.96 ± 51.37 | ||
≥ 55 | 15 | 115.73 ± 42.47 | ||
Lesion site | 0.40 | > 0.05 | ||
Cervical and upper thoracic segment | 22 | 131.00 ± 59.42 | ||
Middle thoracic segment | 36 | 119.50 ± 36.04 | ||
Lower thoracic segment | 28 | 127.36 ± 57.71 | ||
Histopathologic type | 3.40 | < 0.01 | ||
Squamous cell carcinoma | 81 | 122.26 ± 45.91 | ||
Adenocarcinoma | 3 | 196.67 ± 115.14 | ||
Small cell carcinoma | 2 | 128.50 ± 19.09 | ||
X-ray pathologic types | 0.47 | > 0.05 | ||
Marrow | 76 | 126.89 ± 52.3 | ||
Massive | 5 | 120.40 ± 14.00 | ||
Ulcer | 3 | 94.67 ± 23.07 | ||
Narrow | 2 | 110.00 ± 31.11 | ||
Primary foci | 4.55 | < 0.01 | ||
T1 + T2 | 29 | 99.66 ± 22.64 | ||
T3 + T4 | 57 | 137.89 ± 54.95 | ||
Lymph node metastasis | 7.50 | < 0.01 | ||
N0 | 30 | 89.80 ± 12.80 | ||
N1-2 | 56 | 144.50 ± 51.69 | ||
Distant metastasis | 1.02 | > 0.05 | ||
M0 | 65 | 128.15 ± 49.71 | ||
M1 | 21 | 115.23 ± 50.36 | ||
Clinical stage | 2.52 | < 0.01 | ||
I + II | 60 | 115.08 ± 39.76 | ||
III + IV | 26 | 149.40 ± 63.20 |
Table 2 Dynamic changes in vascular endothelial growth factor levels in 83 evaluable esophageal cancer patients
Table 3 Response rate of 83 evaluable esophageal cancer patients n (%)
Group | n | CR | PR | MR | NC |
Drug group | 32 | 10 (31.25) | 13 (40.63) | 7 (21.87) | 2 (6.25) |
Non-drug group | 51 | 26 (50.98) | 14 (27.45) | 7(13.73) | 4 (7.84) |
Table 4 Side effects in 83 evaluable esophageal cancer cases
Side effects | Group | χ2 | P value | |
Drug group | Non-drug group | |||
Dizziness or burnout | 20 | 8 | 19.28 | 0.000 |
Somnolence | 4 | 0 | - | 0.019 |
Grade III-IV esophagitis | 4 | 6 | 0.06 | 0.812 |
Grade III-IV leukocyte decrease | 2 | 5 | 0.03 | 0.864 |
Grade III-IV platelet decrease | 1 | 3 | 0.02 | 0.961 |
Grade III-IV nausea and vomiting | 3 | 14 | 2.913 | 0.089 |
Anaphylaxis | 0 | 0 | - | 1.000 |
- Citation: Yu JP, Sun SP, Sun ZQ, Ni XC, Wang J, Li Y, Hu LJ, Li DQ. Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer. World J Gastroenterol 2014; 20(17): 5098-5103
- URL: https://www.wjgnet.com/1007-9327/full/v20/i17/5098.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i17.5098